Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alex Shimmings

Alexandra has more than 20 years' experience covering pharmaceutical and biotech R&D. An early interest in medicine, and a dawning realization that being a doctor was not for her, led to a degree in Biochemistry and Microbiology at the University of Leeds, and a move to London to pursue a career in medical journalism. Now Scrip's Managing Editor, Alex has held a variety of roles on the publication since starting as a science reporter in 1998. She instigated some of Scrip's signature features, such as the Pipeline Watch and New Active Substance lists, and also casts an editorial eye over the annual Scrip Awards. Alex's main work interests lie in novel drugs and pharmaceutical and biotech R&D, and she also enjoys medical history and current affairs.

Latest From Alex Shimmings

10 US Approval Decisions To Look Out For In Q3

This quarter has already seen a complete response letter for Iterum Therapeutics’ antibiotic sulopenem but a raft of other products are expecting approval decisions from the US Food and Drug Administration in the next three months. With the help of analysts at Biomedtracker, Scrip takes a look at 10 of the more interesting ones.

Approvals Companies

Sanofi Creates ‘Center Of Excellence’ In Pursuit Of mRNA Vaccine Rivals

Sanofi is beefing up its investment in mRNA vaccine technology with a 400m annual injection into a dedicated mRNA Center of Excellence as it seeks to be at the forefront of the next generation of candidates.

Companies Research and Development Strategies

AstraZeneca’s Susan Galbraith To Lead Its Entire Cancer R&D

After more that 10 years at the firm, Susan Galbraith has taken on an expanded role heading up oncology R&D at AstraZeneca.

Appointments Companies

ASCO Data Position Contenders In Battle Of The SERDs

With at least two potential candidates being touted as potential best-in-class by their sponsors, the oral SERD market is shaping up to be highly competitive. Sanofi has taken an early lead in expanding the scope of its Phase III breast cancer program.

ASCO Clinical Trials

ASCO: Adjuvant Breast Cancer Beckons for Merck/AZ’s Lynparza With OlympiA

A decent 42% reduction in the risk of recurrence in high-risk early-stage BRCA mutated disease should open another new market for the leading PARP inhibitor. Data also hint at a survival benefit to come.

ASCO Clinical Trials

Five Late-Breakers To Watch For At ASCO 2021

This year’s American Society of Clinical Oncology meeting is set to take place virtually from 4-8 June, and while many abstracts have now been released for this year’s conference, we take a sneak peek at what is still under wraps, with five of the key late-breaking presentations due to be presented at the plenary session, with input from Biomedtracker and Datamonitor Healthcare.

ASCO Clinical Trials
See All
UsernamePublicRestriction

Register